MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patient, 18 to 70 years of age at time of informed consent
Major depressive disorder without psychotic features as defined by DSM-IV-TR criteria
Inadequate response to ongoing antidepressant treatment, as defined by protocol
Body mass index (BMI) 18 to 38 kg/m2 inclusive
You may not be if
Currently receiving treatment with a combination of antidepressants (two or more), or an adjunctive potentiating treatment as defined by protocol
Previously received RO4917523
History of failure, or utilization during the current episode of Electroconvulsive Therapy (ECT) or repetitive Transcranial Magnetic Stimulation (rTMS)
History of use at any time of Vagus Nerve Stimulation (VNS) or Deep Brain Stimulation (DBS)
Current or past history of bipolar disorder (e.g. manic, hypomanic, or mixed episodes)
Pregnant or lactating women
Clareo Health | MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy
